These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

A human-derived, ultra-long-acting GLP-1 injection independently researched and developed by Innogen, a Shanghai-based ...

Innogen, a Shanghai-based medical technology company, announced that its independently developed, human-derived, ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

SGLT2 inhibitors and GLP-1 agonists also reduced the risk ... s age into account when deciding which medications to prescribe for type 2 diabetes. Although all of the patients in this review ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The study reveals SGLT-2is are linked to fewer COPD exacerbations in type 2 diabetes, suggesting a need for further clinical ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight loss medications known as GLP-1 receptor agonists, including the popular name brands Ozempic ...

Learn about the financial strain caused by the skyrocketing demand and costs of GLP-1 drugs, and how health plans and providers are struggling to balance it.